StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research report report published on Tuesday. The firm issued a hold rating on the stock.
Several other equities analysts also recently weighed in on DBVT. HC Wainwright increased their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. JMP Securities restated a "market outperform" rating and set a $10.00 price target on shares of DBV Technologies in a research note on Friday, January 10th.
View Our Latest Analysis on DBVT
DBV Technologies Price Performance
DBVT traded up $0.14 during trading on Tuesday, reaching $4.40. 8,122 shares of the stock were exchanged, compared to its average volume of 93,289. The business's 50 day moving average price is $3.98 and its two-hundred day moving average price is $3.85. The company has a market capitalization of $90.51 million, a price-to-earnings ratio of -0.98 and a beta of 0.67. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.09.
Institutional Investors Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is currently owned by institutional investors.
DBV Technologies Company Profile
(
Get Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Recommended Stories
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
